In another example of the blinding speed at which science is moving during the pandemic era, researchers at Aarhus University in Denmark will start a clinical trial of a drug named camostat mesylate tomorrow—barely 1 month after a Cell paper showed the compound can prevent the novel coronavirus, SARS-CoV-2, from entering human cells “If we are to have an impact on the rising epidemic, then we have to act right now,” says Ole Søgaard, the infectious disease physician leading the study